Block on Trump's Asylum Ban Upheld by Supreme Court
The U.S. Food and Drug Administration (FDA) is directing the manufacturers of all approved Attention Deficit Hyperactivity Disorder (ADHD) drugs to alert patients to possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, and to advise them of precautions that can be taken. The FDA has received reports of sudden death in ADHD patients with underlying serious heart problems or defects, and reports of stroke and heart attack in adults with certain risk factors. The medicines that are the focus of this FDA action include Adderall, Concerta, Methyline, and Ritalin. Read the FDA Press Release.